[HTML][HTML] Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
H Sofen, S Smith, RT Matheson, CL Leonardi… - Journal of Allergy and …, 2014 - Elsevier
Background IL-23 expression is increased in psoriatic lesions and might regulate TH 17 T-
cell counts in patients with psoriasis. Objectives We sought to test a novel IL-23–specific
therapeutic agent for the treatment of psoriasis. Methods In this randomized, double-blind,
placebo-controlled study the safety, tolerability, and clinical response of guselkumab, an anti–
IL-23–specific mAb, were evaluated in patients with moderate-to-severe plaque psoriasis. A
total of 24 patients were randomized to receive a single dose of placebo or 10, 30, 100, or …
cell counts in patients with psoriasis. Objectives We sought to test a novel IL-23–specific
therapeutic agent for the treatment of psoriasis. Methods In this randomized, double-blind,
placebo-controlled study the safety, tolerability, and clinical response of guselkumab, an anti–
IL-23–specific mAb, were evaluated in patients with moderate-to-severe plaque psoriasis. A
total of 24 patients were randomized to receive a single dose of placebo or 10, 30, 100, or …